

	ACCREDITATION DOCUMENT	F-06/02 Issue Date: 18/08/2020 Rev. No: 09 LAB 160
-----------------------------------------------------------------------------------	-----------------------------------	-----------------------------------------------------------------------

Accreditation No: LAB 160

Awarded to

**Drugs Testing Laboratory Punjab Multan, Near Kidney Centre,
Muzaffar Garrh Road, Multan, Pakistan**

The scope of accreditation is in accordance with the standard specifications outlined in the following page(s) of this document. The accredited scope shall be visible and legible in areas such as customer service, sample-receiving section etc and shall not mislead its users.

The accreditation was first time granted on **31-07-2018** by Pakistan National Accreditation Council.

The laboratory complies with the requirements of **ISO/IEC 17025:2017**.

The accreditation requires regular surveillance, and is valid until **30-07-2024**.

The decision of accreditation made by Pakistan National Accreditation Council implies that the organization has been found to fulfill the requirements for accreditation within the scope.

The organization however, itself is responsible for the results of performed measurements/tests.

PAKISTAN NATIONAL ACCREDITATION COUNCIL

22-09-2021

Date

Sd

Director General

	ACCREDITATION DOCUMENT	F-06/02 Issue Date: 18/08/2020 Rev. No: 09 LAB 160
-----------------------------------------------------------------------------------	-----------------------------------	-----------------------------------------------------------------------------------------

Testing Laboratory.

Accreditation Scope of Drugs Testing Laboratory, Multan, Pakistan.

Permanent laboratory premises

Materials/Products tested	Testing field (e.g. environmental testing or mechanical testing)	Types of test/ Properties measured	Reference to standardized method (e.g. ISO 14577-1:2003)/ Internal method reference
Paracetamol Active Pharmaceutical Ingredient	Pharmaceutical Testing	Quantitative Analysis	Internal Method (DTLM-PM-SP-001)/UV-absorbance/ UV-Visible Spectrophotometer
Paracetamol Tablet dosage Form	Pharmaceutical Testing	Quantitative Analysis	BP-2017, III-1005 /UV-absorbance/ UV-Visible Spectrophotometer
Ibuprofen Active Pharmaceutical Ingredient	Pharmaceutical Testing	Quantitative Analysis	Internal Method (DTLM-IB-SP-002) /Liquid Chromatography/ HPLC
Ibuprofen Tablet dosage Form	Pharmaceutical Testing	Quantitative Analysis	USP-2017, Vol No. 4-Page No. 4558 /Liquid Chromatography/ HPLC
Paracetamol Tablet dosage Form	Pharmaceutical Testing	Weight Variation	BP-2019, V-A402/ Appendix XII C Weighing Balance
Ribavirin Tablet	Pharmaceutical Testing	Weight Variation	BP-2019, V-A402/ Appendix XII C Weighing Balance
	Pharmaceutical Testing	Quantitative Analysis	USP-2019, Vol No.2-Page No. 3838/ HPLC

22-09-2021
Date

Sd _____
Director



**ACCREDITATION
DOCUMENT**

F-06/02
Issue Date: 18/08/2020
Rev. No: 09
LAB 160

Allopurinol Tablet	Pharmaceutical Testing	Weight Variation	BP-2019, V-A402/ Appendix XII C Weighing Balance
	Pharmaceutical Testing	Quantitative Analysis	BP-2019, III-126/ UV-Spectroscopy
Mebeverine Tablet	Pharmaceutical Testing	Quantitative Analysis	BP-2019, III-880/ UV-Spectroscopy
Ciprofloxacin Infusion	Pharmaceutical Testing	pH	USP 2019, Vol No.1-Page No. 994 / pH meter
		Extractable Volume	USP 2019, Vol No.4- (697) 6860 / Measuring Cylinder
Sitagliptin Tablet	Pharmaceutical Testing	Disintegration	USP 2019, Vol No.2-Page No.4014 / Disintegration Apparatus
Water for Injection	Pharmaceutical Testing	Conductivity	USP 2019, Vol No.4-(645) 6796 / Conductivity meter
Propranolol Tablet	Pharmaceutical Testing	Assay (UV-Visible Spectrophotometer)	BP 2020, Volume III, (1182)

22-09-2021
Date

Sd
Director



ACCREDITATION DOCUMENT

F-06/02
Issue Date: 18/08/2020
Rev. No: 09
LAB 160

Atenolol Tablet	Pharmaceutical Testing	Assay (UV-Visible Spectrophotometer)	BP 2020, Volume III, (174)
Furosemide Injection	Pharmaceutical Testing	Assay (UV-Visible Spectrophotometer)	BP 2020, Volume III, (676,677)
Indomethacin Capsule	Pharmaceutical Testing	Assay (UV-Visible Spectrophotometer)	BP 2020, Volume III, (776)
Isotretinoin Capsule	Pharmaceutical Testing	Assay (UV-Visible Spectrophotometer)	BP 2020, Volume III, (819)
Isotretinoin Gel	Pharmaceutical Testing	Assay (UV-Visible Spectrophotometer)	BP 2020, Volume III, (820)
Metformin Tablet	Pharmaceutical Testing	Assay (UV-Visible Spectrophotometer)	BP 2020, Volume III, (912)
Naproxen Tablet	Pharmaceutical Testing	Assay (UV-Visible Spectrophotometer)	BP 2020, Volume III, (1010)
Dydrogesterone Tablet	Pharmaceutical Testing	Assay (UV-Visible Spectrophotometer)	BP 2020, Volume III, (566)
Metronidazole Infusion	Pharmaceutical Testing	Assay (UV-Visible Spectrophotometer)	BP 2020, Volume III, (953)

22-09-2021
Date

Sd
Director



**ACCREDITATION
DOCUMENT**

F-06/02
Issue Date: 18/08/2020
Rev. No: 09
LAB 160

Fluoxetine Capsule	Pharmaceutical Testing	Assay (HPLC)	BP 2020, Volume III (646)
Naproxen Tablet	Pharmaceutical Testing	Assay (HPLC)	USP 42, Volume II, (3079)
Loratadine Tablet	Pharmaceutical Testing	Assay (HPLC)	USP 42, Volume II (2624)
Amoxicillin Capsule	Pharmaceutical Testing	Assay (HPLC)	USP 42, Volume I, (295)
Carvedilol Tablet	Pharmaceutical Testing	Assay (HPLC)	USP 42, Volume I (775)
Candesartan Tablet	Pharmaceutical Testing	Assay (HPLC)	USP 42, Volume I (700)
Levetiracetam Tablet	Pharmaceutical Testing	Assay (HPLC)	USP 42, Volume II (2529)
Ibuprofen Oral Suspension	Pharmaceutical Testing	Assay (HPLC)	USP 42, Volume II (3834)
Metronidazole tablet	Pharmaceutical Testing	Disintegration	BP 2020, Volume III, (955) BP 2020, V-A384, Appendix XII A

22-09-2021
Date

Sd
Director



**ACCREDITATION
DOCUMENT**

F-06/02
Issue Date: 18/08/2020
Rev. No: 09
LAB 160

Metformin Tablet	Pharmaceutical Testing	Dissolution	BP 2020, Volume III, (930)
Paracetamol Tablet	Pharmaceutical Testing	Dissolution	BP 2020, Volume III, (1086)
Naproxen Tablet	Pharmaceutical Testing	Dissolution	BP 2020, Volume III, (1010)
Acyclovir Tablet	Pharmaceutical Testing	Weight Variation	BP 2020, Volume V (A408) Appendix XII C
Aminophylline Tablet	Pharmaceutical Testing	Weight Variation	BP 2020, Volume V (A408) Appendix XII C
Carbimazole Tablet	Pharmaceutical Testing	Weight Variation	BP 2020, Volume V (A408) Appendix XII C
Metformin Tablet	Pharmaceutical Testing	Weight Variation	BP 2020, Volume V (A408) Appendix XII C
Metoprolol Tablet	Pharmaceutical Testing	Weight Variation	BP 2020, Volume V (A408) Appendix XII C
Naproxen Tablet	Pharmaceutical Testing	Weight Variation	BP 2020, Volume V (A408) Appendix XII C

22-09-2021
Date

Sd
Director



ACCREDITATION DOCUMENT

F-06/02
Issue Date: 18/08/2020
Rev. No: 09
LAB 160

Propranolol Tablet	Pharmaceutical Testing	Weight Variation	BP 2020, Volume V (A408) Appendix XII C
Fluvoxate Tablet	Pharmaceutical Testing	Weight Variation	BP 2020, Volume V (A408) Appendix XII C
Ramipril Tablet	Pharmaceutical Testing	Weight Variation	BP 2020, Volume V (A408) Appendix XII C
Pyridoxine Tablet	Pharmaceutical Testing	Weight Variation	BP 2020, Volume V (A408) Appendix XII C
Amikacin Injection	Pharmaceutical Testing	pH	BP 2020 Volume III (132)
Dexamethasone sodium phosphate Injection	Pharmaceutical Testing	pH	BP 2020 Volume III (495)
Isosorbide Dinitrate Injection	Pharmaceutical Testing	pH	BP 2020 Volume III (811)
Ketamine Injection	Pharmaceutical Testing	pH	BP 2020, Volume III (827)
Mannitol Infusion	Pharmaceutical Testing	pH	BP 2020, Volume III (899)

22-09-2021
Date

Sd
Director



**ACCREDITATION
DOCUMENT**

F-06/02
Issue Date: 18/08/2020
Rev. No: 09
LAB 160

Metoclopramide Injection	Pharmaceutical Testing	pH	BP 2020, Volume III (945)
Metronidazole Infusion	Pharmaceutical Testing	pH	USP 2019, Volume II (2898)
Midazolam Injection	Pharmaceutical Testing	pH	BP 2020, Volume III (964)
Tranexamic Acid Injection	Pharmaceutical Testing	pH	BP 2020, Volume III (1370)
Valproate Sodium Injection	Pharmaceutical Testing	pH	USP 2019, Volume II (4532)
Tranexamic Acid Injection	Pharmaceutical Testing	pH	BP 2021, Volume III (1401)
Valproate Sodium Injection	Pharmaceutical Testing	pH	USP 2021, GUID-8728583B-DD52-4C98-8A46-85077D576202_4_en-US
Metronidazole Injection (100 mL)	Pharmaceutical Testing	Extractable Volume	USP 2021, (697) GUID-36AE7C6F-5983-4F42-9426-24574CEDB1A4_1_en-US
Metronidazole Infusion (100 mL)	Pharmaceutical Testing	Extractable Volume	BP 2021, V-A417 Appendix XIIC

22-09-2021
Date

Sd
Director

	ACCREDITATION DOCUMENT	F-06/02 Issue Date: 18/08/2020 Rev. No: 09 LAB 160
-----------------------------------------------------------------------------------	-----------------------------------	-----------------------------------------------------------------------------------------

Oxytetracycline Injection (50 mL)	Pharmaceutical Testing	Extractable Volume	USP 2021, (697) GUID-36AE7C6F-5983-4F42-9426- 24574CEDB1A4_1_en-US
Potassium Chloride Injection (20 mL, 25 mL)	Pharmaceutical Testing	Extractable Volume	BP 2021, V-A417 Appendix XIIC
Sodium Bicarbonate Injection (20 mL)	Pharmaceutical Testing	Extractable Volume	BP 2021, V-A417 Appendix XIIC
Sodium Chloride Infusion (100 mL)	Pharmaceutical Testing	Extractable Volume	BP 2021, V-A417 Appendix XIIC
Sodium Chloride Injection (100 mL)	Pharmaceutical Testing	Extractable Volume	USP 2021, (697) GUID-36AE7C6F-5983-4F42-9426- 24574CEDB1A4_1_en-US
Mannitol Infusion (500 mL)	Pharmaceutical Testing	Extractable Volume	BP 2021, V-A417 Appendix XIIC
Sulfadimidine Injection (100mL)	Pharmaceutical Testing	Extractable Volume	BP 2021, V-A417 Appendix XIIC

22-09-2021
Date

Sd
Director